Applied BioMath, LLC Announces Quantitative Systems Pharmacology (QSP) Industry & Academia Symposium Speaker Lineup


LINCOLN, Mass., Jan. 12, 2018 — Applied BioMath (, the industry-leader in applying mechanistic modeling, simulation, and analysis, to drug research and development, today announced the speaker lineup for the upcoming QSP Industry & Academia Symposium. The event will take place Wednesday, February 7, 2018 from 5:00 p.m. to  8:30 p.m. at the Cambridge Innovation Center in Cambridge, MA.

This QSP Industry & Academia Symposium will feature presentations from Richard Allen, PhD,  Senior Principal Scientist at Pfizer and Carissa Young, PhD, Senior Scientist at Applied BioMath along with networking opportunities.

Richard Allen, PhD, is presenting a talk titled “Assessing Fructose as a Biomarker by Modeling the Metabolic Fate of Fructose in Essential Fructosuria Subjects” in which he will discuss the development and use of a mathematical model to investigate the adaptations to altered fructose metabolism in people with a rare benign genetic deficiency in ketohexokinase (KHK). The findings have implications for drug discovery and development, suggesting that the therapeutic targeting of fructose metabolism could lead to unexpected metabolic adaptations, potentially due to a physiological response to high fructose conditions.

Carissa Young, PhD, presently a Senior Scientist at Applied BioMath, is presenting research that she completed during her Postdoc at MIT under the direction of Dr. Douglas A. Lauffenburger. Dr. Young's talk, “3D Metastatic Breast Cancer Model Recapitulates Dormancy and Emergence,” will uncover how a 3D metastatic model composed of human hepatocytes, non-parenchymal cells, and breast cancer cell lines enabled the evaluation of tumor growth, dormancy, and emergence amongst multiple donors, as a consequence of chemotherapies and inflammatory stimuli. The results recapitulate human disease pathophysiology using an all-human ex vivo microphysiological system, which may ultimately improve therapeutic strategies that target breast cancer dormancy and emergence.

“I am passionate about fostering the QSP community and building a network of resources together. The presentations spark engaging group discussions as we continue to share challenges and best practices with one another.”

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

For more information about this QSP Industry and Academia Symposium, and to register, visit

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.  Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.  The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic.   For more information about Applied BioMath and its services, visit

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
[email protected]

Cision View original content with multimedia:–academia-symposium-speaker-lineup-300582083.html

SOURCE Applied BioMath, LLC

Related Links

Powered by WPeMatico